Quoin Pharmaceuticals (QNRX) CFO Sally Lawlor Buys Stock

What Happened
Sally Bridget Lawlor, CFO of Quoin Pharmaceuticals Ltd. (QNRX), purchased ADSs in a private placement on August 31, 2026. The filing reports acquisition of 10,244 shares at $4.88 per unit for a reported cash outlay of $49,991. The filing also shows acquisition of 5,122 derivative instruments (warrants) tied to that placement (no cash amount listed for the derivative line).

Key Details

• Transaction date: 2026-08-31; Form 4 filed 2026-09-01 (appears timely).
• Purchase details: 10,244 shares @ $4.88 = $49,991 (reported cash paid). Additional 5,122 derivative instruments (warrants) were issued (amount for derivative reported as N/A).
• Structure: ADSs and accompanying warrants were issued together at a combined purchase price of $4.88 (private placement with 50% warrant coverage).
• ADS mechanics: Each ADS represents 35 ordinary shares of the issuer (per footnote). If the reported share count refers to ADSs, 10,244 ADSs would equate to 358,540 underlying ordinary shares.
• Warrants: Exercisable immediately upon issuance subject to a beneficial ownership cap; expire upon the earlier of (i) five years from issuance or (ii) 30 days after a public announcement that the primary endpoint has been met in the CL-QRX003-004 Netherton Syndrome trial.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.

Context

• This was a purchase in a private placement, not an open-market buy, and included 50% warrant coverage (one warrant for every two ADSs). Purchases by insiders can be interpreted by investors as a vote of confidence, but filings are factual and do not explain motive.
• The derivative line reflects issuance of warrants (not an option exercise). The warrants are immediately exercisable but limited by a beneficial ownership cap and have a potentially accelerated expiration tied to clinical trial results.